Several studies have shown in patients with diabetes that the incidence of acute myocardial infarction [
13], death from CV disease [
14] and especially from CAD [
15] has markedly decreased over the last decades due to a better control of major risk factors. Nevertheless, CV morbidity and mortality remain significantly higher compared to the nondiabetic population. A marked decrease in the prevalence of SMI has also been recently reported in patients with diabetes [
9]. However, SMI is more prevalent in some subgroups.
This study is the first one to test the validity of the 2019 ESC/EASD guidelines for CV risk stratification [
1], restricting CAD assessment to some very high risk patients. Our results show that among asymptomatic diabetic patients with very high CV risk criteria, a high CAC score was associated with a three-fold increase in SMI risk and was an independent predictor of SMI. Restricting SMI screening to those with severe TOD or high CAC score appears to be a good compromise, selecting all patients with coronary stenoses eligible for revascularization, at a controlled cost.
Silent myocardial ischemia in diabetes
Myocardial infarction is often silent in patients with diabetes [
16,
17]. The prevalence of silent myocardial infarction diagnosed with resting ECG is about 4% and is markedly higher with echocardiography, myocardial scintigraphy or cardiac magnetic resonance [
18]. The prevention of silent myocardial infarction is therefore challenging and might be possible with an earlier detection of CAD.
The prevalence of SMI in the diabetic population ranges from 6% [
19] to 35% [
7]. In our study, using stress myocardial scintigraphy, SMI was diagnosed in about 10% of the patients. This rather low SMI prevalence despite the very high risk patient profile is in line with a recent report [
9]. Significant CAD on angiography was reported in 30% [
20] to 90% [
21] of the patients with SMI; 50% in the current study. Indeed, ischaemia is not always associated with coronary stenoses and may be favoured by functional disorders including endothelial dysfunction, abnormal microcirculation and abnormal coronary reserve [
22,
23]; therefore, only few patients with SMI are eligible to revascularization [
20,
24]. Noticeably, SMI is predictive of worse CV events [
7,
25], especially in the presence of coronary stenoses [
20] or with a high CAC score [
26], and adds to the prediction above and beyond routine risk assessment [
11].
Detection of SMI should promote medical therapy intensification, including an optimal control of risk factors, and may lead to consider coronary revascularization when appropriate [
27]. In addition, some CV outcomes trials testing the new glucose-lowering drugs, GLP1-RAs and SGLT2 inhibitors, suggest that these drugs may be beneficial in patients with evidence of SMI and in those with coronary stenoses, thus definitely in very high risk patients [
28,
29]. However, this needs to be specifically tested in further studies. Furthermore, screening for SMI does not clearly translate into a reduction in CV events. A recent meta-analysis of randomized controlled trials, focusing on SMI screening and/or treatment, showed that non-invasive screening significantly reduced cardiac events by 27%, a result mostly driven by a decrease in non-fatal myocardial infarction and hospitalization for heart failure [
10].
A lot of investigations are still being performed to assess patients for SMI, whereas the potential harms of screening procedures must be carefully evaluated and the cost–benefit ratio of screening has not been definitely established yet. Thus, there is a need to improve SMI screening efficacy. Some markers of SMI have recently been suggested, including resting left ventricular global longitudinal strain [
30] and serum oncostatin M, a novel biomarker [
31], and need to be tested in further studies. Screening for SMI should probably only be considered in very high risk patients, which would improve the estimation of CV risk and, ultimately, more accurately set therapeutic goals and choose optimal treatment. Indeed, the best strategy to identify silent CAD in patients with diabetes remains unclear. The American Diabetes Association (ADA) guidelines recommend to refrain from screening for silent CAD in asymptomatic individuals with diabetes [
32]. The 2019 ESC/EASD guidelines [
1] suggested a new CV risk stratification to help selecting patients who should benefit from CV disease and especially SMI screening, in order to set appropriate therapeutic targets and optimize treatments, with a major role for GLP1-RAs and SGLT2 inhibitors. This stratification is primarily based on simple, currently available risk criteria including the age, type and duration of diabetes, the number of associated risk factors and the presence or absence of TOD but also involves some risk modifiers including CAC score that could reclassify more accurately the CV risk. According to these guidelines, screening for SMI may be indicated in the very high risk patients with severe TOD and/or high CAC score.
In our study, we included asymptomatic patients with diabetes and very high CV risk criteria according to the ESC/EASD guidelines [
1]. Male gender, a long duration of diabetes, low HDL-cholesterol level and the presence of POAD were associated with a high risk of SMI, in agreement with previous publications. Indeed, diabetic retinopathy [
33], nephropathy [
19,
34], cardiac autonomic neuropathy [
35] and POAD [
20,
33] have been shown to be associated with a higher prevalence of SMI. Chronic kidney disease is an independent risk factor for multi-vessel CAD [
36,
37], and screening for CAD is important in the preoperative evaluation of kidney transplant candidates [
38]. Similarly, POAD is a strong predictor of CAD [
39]. Interestingly, in our study, the prevalence of SMI was higher in patients with severe TOD (POAD or severe nephropathy) compared to those without. This finding is supportive of the role of this very high risk component as defined in the ESC/EASD guidelines in selecting patients for SMI screening.
Role of CAC score in the detection of silent myocardial ischemia
CAC score is a safe, rapid and inexpensive method to assess the volume of coronary calcifications. It is assumed that each calcification equals an atherosclerotic plaque. Among asymptomatic patients with diabetes, the prevalence of elevated CAC score is at or above 20%, that is higher than in the nondiabetic population [
2,
40]. The predictive value for mortality of an elevated CAC score is increased in patients with diabetes compared to nondiabetic individuals [
2]. CAC score was shown to improve CV risk stratification on top of traditional risk factors [
2,
40,
41], and to predict mortality in addition to scintigraphy both in symptomatic and asymptomatic patients [
26,
42]. CAC score is considered in the ADA and ESC/EASD guidelines as a risk modifier [
1,
32]. In addition, a meta-analysis has reported a quantitative relationship between CAC score level and the likelihood of SMI diagnosis during stress scintigraphy [
5]. In our study, CAC score was ≥ 100 AU in 45% of our patients, and high CAC scores were associated with a higher risk of SMI. Interestingly, multivariable analyses showed that CAC ≥ 100 AU – but not POAD or severe TOD—was independently associated with SMI.
We evaluated various strategies to identify the patients with a high likelihood of SMI: performing a stress myocardial scintigraphy in patients with either severe TOD only, or high CAC score only, or in patients with severe TOD or high CAC score in the absence of severe TOD, and finally in those with any TOD (mild or severe). When compared to stress scintigraphy in the overall population (reference data), the third strategy led to perform CAC score measurements in 62% of the total population with a marked reduction (by 39 or 53% when considering the thresholds of 100 or 400 AU for CAC score, respectively) in the number of scintigraphies and a reduction in the number of coronary angiographies. This strategy, using the threshold of 100 AU for CAC score, identified all the patients with significant stenoses including all those eligible for coronary revascularization. Thus, this strategy appeared as the most effective. The three-risk factors criterion, another component of the very high risk profile according to ESC/EASD guidelines, was present in more than 90% of our study population, suggesting that this criterion does not allow an effective selection of patients who should be screened for SMI.
Thus, those results emphasize the role of CAC as a useful marker of SMI in patients with diabetes but no evidence of TOD. Moreover, in a randomized study including patients with no history of CV disease, the patients who were randomized to perform CAC measurement had better subsequent control of their risk factors compared to patients who did not have CAC score measurement; and CAC magnitude was reported to identify patients most likely to benefit from statins in primary CV prevention [
43]. CAC score may help practitioners and patients in decision making and encourage the initiation and continuation of preventive therapies. In this respect, it should be emphasized that our strategy including CAC measurement in patients with no evidence of TOD, detected all the patients with significant stenoses eligible for coronary revascularization. Using CAC imaging and secondarily stress scintigraphy may improve diagnostic performance and appear to be a cost-effective strategy, as previously suggested [
6,
44]. However, whether or not the detection of silent CAD using CAC score measurement may improve clinical outcomes remains to be shown in specifically designed prospective studies.
Limitations and strengths
Our study has some limitations. First, the study was retrospective and the results need to be confirmed in a prospective study including a broader population of very high risk patients with diabetes. Second, the participants were recruited in one hospital center, and that could limit the generalizability of our results. However, the study population was reasonably large and relatively homogeneous since all the patients were hospitalized in the same diabetes center and were at very high CV risk according to the ESC/EASD guidelines but with no history or symptoms of CV disease. Regarding to the type of diabetes, the large majority of our patients had type 2 diabetes, which precludes a definitive conclusion for patients with type 1 diabetes. Third, left ventricular hypertrophy, one of the TOD reported in guidelines, could not be considered as echocardiography was not always available. Therefore, the study might have missed some patients that the guidelines define as very high risk. Nevertheless, information about all the other TODs was available. Fourth, the cross-sectional design of our study prevents us from evaluating the impact of the tested strategies on CV outcomes.
Nevertheless, our study has major strengths, as the same protocol was applied to the total population, stress scintigraphy was always performed in the same nuclear medicine department and CAC score was measured in a unique radiology center.